https://www.pharmaradar360.com/article/biotech-ipos-lead-2026-us-market-overshadowing-ai-firms-like-anthropic-da0817446f761482Pharma Surgeen2026-07-21T16:17:57.000ZBiotech IPOs lead 2026 US market, overshadowing AI firms like Anthropichttps://www.pharmaradar360.com/article/influenza-vaccines-marketed-in-the-uk-d048acae18525d12Pharma Surgeen2026-07-21T16:11:34.000ZInfluenza vaccines marketed in the UKhttps://www.pharmaradar360.com/article/inside-semmelweis-doceree-s-ai-bet-on-pharma-marketing-079248187b1f612dPharma Surgeen2026-07-21T16:10:54.000ZInside Semmelweis: Doceree's AI Bet on Pharma Marketinghttps://www.pharmaradar360.com/article/novo-sues-lilly-alleging-misleading-advertising-of-obesity-drugs-15097471233056ffPharma Surgeen2026-07-21T16:07:32.000ZNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugshttps://www.pharmaradar360.com/article/newly-upgraded-one-lincoln-tower-lands-its-first-biotech-tenant-fc0dabd84b23490cPharma Surgeen2026-07-21T16:07:27.000ZNewly upgraded One Lincoln tower lands its first biotech tenanthttps://www.pharmaradar360.com/article/national-mycobacterium-reference-service-south-user-handbook-ed8faef0a68eee13Pharma Surgeen2026-07-21T16:04:10.000ZNational mycobacterium reference service - South: user handbookhttps://www.pharmaradar360.com/article/mid-year-check-in-has-pharma-s-commercial-caution-lifted-609ce4c9a005c1afPharma Surgeen2026-07-21T15:55:54.000ZMid-Year Check-In: Has Pharma's Commercial Caution Lifted?https://www.pharmaradar360.com/article/why-japan-is-a-global-destination-for-regenerative-medicine-cb31225b9ea1fd84Pharma Surgeen2026-07-21T15:54:46.000ZWhy Japan is a global destination for regenerative medicinehttps://www.pharmaradar360.com/article/new-bill-senator-elizabeth-warren-introduces-s-4987-pharmaceutical-investment-ov-971025dd8de54856Pharma Surgeen2026-07-21T15:45:00.000ZNew Bill: Senator Elizabeth Warren introduces S. 4987: Pharmaceutical Investment Oversight and Accountability Acthttps://www.pharmaradar360.com/article/12a0e8e597109720Pharma Surgeen2026-07-21T15:30:00.000Z譲渡制限付株式報酬としての自己株式の処分に関するお知らせhttps://www.pharmaradar360.com/article/immunisation-3eb017cda8d80ce8Pharma Surgeen2026-07-21T15:29:34.000ZImmunisationhttps://www.pharmaradar360.com/article/masimo-keeps-634m-smartwatch-award-and-moves-to-appeal-b783ade7413f9fa4Pharma Surgeen2026-07-21T15:29:31.000ZMasimo keeps $634m smartwatch award and moves to appealhttps://www.pharmaradar360.com/article/novo-sues-lilly-after-alleged-misleading-and-false-advertising-campaign-8cbe7074ad3068b2Pharma Surgeen2026-07-21T15:25:25.000ZNovo sues Lilly after alleged misleading and false advertising campaignhttps://www.pharmaradar360.com/article/bacteriology-reference-department-user-manual-920f0fc90b06e74bPharma Surgeen2026-07-21T15:24:29.000ZBacteriology reference department user manualhttps://www.pharmaradar360.com/article/biotech-ipo-gains-crush-ai-listings-with-standout-55-return-7e0811f9b52cb4f6Pharma Surgeen2026-07-21T14:26:11.000ZBiotech IPO Gains Crush AI Listings With Standout 55% Returnhttps://www.pharmaradar360.com/article/investigational-once-weekly-oral-hiv-treatment-regimen-of-islatravir-and-lenacap-8c13d824e3fa2349Pharma Surgeen2026-07-21T14:22:35.000ZInvestigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapyhttps://www.pharmaradar360.com/article/why-is-agio-stock-falling-today-d67c283664fb9f69Pharma Surgeen2026-07-21T14:09:02.000ZWhy Is AGIO Stock Falling Today?https://www.pharmaradar360.com/article/jupiter-enters-psychedelics-space-with-100m-deal-for-pharmala-s-mdma-drug-b3ab855c44ee8e85Pharma Surgeen2026-07-21T14:00:40.000ZJupiter enters psychedelics space with $100M deal for PharmAla's MDMA drughttps://www.pharmaradar360.com/article/collegium-pharmaceutical-headquarters-lease-adds-to-one-lincoln-s-leasing-moment-43282e53efea013ePharma Surgeen2026-07-21T13:55:38.000ZCollegium Pharmaceutical Headquarters Lease Adds to One Lincoln's Leasing Momentum in Downtown Bostonhttps://www.pharmaradar360.com/article/this-new-biotech-might-have-solved-the-problem-with-long-term-space-missions-27bb20f98d5c7155Pharma Surgeen2026-07-21T13:47:00.000ZThis New Biotech Might Have Solved The Problem With Long-Term Space Missionshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-on-daikyo-deal-looks-closer-to-fully-valued-8b10f63a0ad5071aPharma Surgeen2026-07-21T13:45:29.000ZWest Pharmaceutical Services (WST) On Daikyo Deal Looks Closer To Fully Valuedhttps://www.pharmaradar360.com/article/beat-the-heat-hot-weather-advice-0f3647cb000e780cPharma Surgeen2026-07-21T13:37:06.000ZBeat the heat: hot weather advicehttps://www.pharmaradar360.com/article/anthropic-deepens-work-with-rare-disease-drugs-240c9c228f6da42ePharma Surgeen2026-07-21T13:36:28.000ZAnthropic deepens work with rare disease drugshttps://www.pharmaradar360.com/article/report-ri-fugitive-likely-worked-as-biotech-executive-e8ffe55a0d3ef161Pharma Surgeen2026-07-21T13:31:46.000ZReport: RI fugitive likely worked as biotech executivehttps://www.pharmaradar360.com/article/update-on-construction-of-new-plasma-derived-therapies-manufacturing-facility-in-d1631dff5b1be72fPharma Surgeen2026-07-21T13:28:13.000ZUpdate on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/20-000-takeda-employees-voted-to-select-four-new-global-corporate-social-respons-4ce0a7cb1b55185dPharma Surgeen2026-07-21T13:28:13.000Z20,000+ Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-announces-completion-of-acquisition-of-own-shares-takeda-pharmaceuticals-1690c2b8dd2b1291Pharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces Completion of Acquisition of Own Shares | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/filing-of-corporate-governance-report-to-the-tokyo-stock-exchange-takeda-pharmac-7d9747a68e4a6c88Pharma Surgeen2026-07-21T13:28:13.000ZFiling of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-announces-the-pricing-terms-of-the-previously-announced-cash-tender-offer-6b835e699995b023Pharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takedahttps://www.pharmaradar360.com/article/takeda-announces-new-assignments-of-directors-10a83953d9c25a4dPharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces New Assignments of Directorshttps://www.pharmaradar360.com/article/statement-on-inadvertent-abstract-disclosure-for-oveporexton-tak-861-by-world-sl-1f18034b19962b0aPharma Surgeen2026-07-21T13:28:08.000ZStatement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congresshttps://www.pharmaradar360.com/article/takeda-reports-third-quarter-fy2025-results-takeda-pharmaceuticals-14036fe34e09df4fPharma Surgeen2026-07-21T13:28:08.000ZTakeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-completed-issuance-of-new-shares-and-disposal-of-treasury-shares-under-th-a48691ebb9c8bbe0Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-phase-3-study-results-in-pediatric-ulcerative-colitis-a9ef7719579194c5Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Phase 3 Study Results in Pediatric Ulcerative Colitishttps://www.pharmaradar360.com/article/u-s-fda-accepts-takeda-sbla-for-review-in-pediatric-uc-and-crohn-s-disease-e5af34c8063bc00fPharma Surgeen2026-07-21T13:28:08.000ZU.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Diseasehttps://www.pharmaradar360.com/article/rusfertides-phase-3-trial-for-polycythemia-vera-at-asco-2025-1a2bc3f4b3f44199Pharma Surgeen2026-07-21T13:28:08.000ZRusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025https://www.pharmaradar360.com/article/takeda-presents-long-term-data-from-advance-cidp-3-trial-of-hyqvia-733e0fb7ab2e8439Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIAhttps://www.pharmaradar360.com/article/takeda-to-hold-third-quarter-fy2022-earnings-call-on-february-2-2c1070c50282df17Pharma Surgeen2026-07-21T13:28:08.000ZTakeda to Hold Third Quarter FY2022 Earnings Call on February 2https://www.pharmaradar360.com/article/notice-concerning-withdrawal-of-shelf-registration-statement-and-filing-of-new-s-3f2e1b938aa6ce0aPharma Surgeen2026-07-21T13:28:02.000ZNotice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japanhttps://www.pharmaradar360.com/article/adzynma-receives-european-commission-approval-as-first-recombinant-adamts13-ther-f84e23ea1fc15610Pharma Surgeen2026-07-21T13:28:02.000ZADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTPhttps://www.pharmaradar360.com/article/u-s-fda-approves-takeda-s-takhzyro-lanadelumab-flyo-to-prevent-hereditary-angioe-69d4a44f3b2773d8Pharma Surgeen2026-07-21T13:28:02.000ZU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Olderhttps://www.pharmaradar360.com/article/takeda-to-acquire-exclusive-worldwide-ex-china-license-of-hutchmed-s-fruquintini-9ca0be57679fe064Pharma Surgeen2026-07-21T13:28:02.000ZTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitorhttps://www.pharmaradar360.com/article/dhsc-annual-statement-on-research-integrity-2025-to-2026-0e27c671da508172Pharma Surgeen2026-07-21T13:27:10.000ZDHSC annual statement on research integrity: 2025 to 2026https://www.pharmaradar360.com/article/fugitive-may-have-had-secret-career-in-biotech-b2a3f87bdcebb531Pharma Surgeen2026-07-21T13:25:00.000ZFugitive May Have Had Secret Career in Biotechhttps://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-novo-suing-lilly-over-deceptive-ads-a-fugitive-46f2f64ca44ccd01Pharma Surgeen2026-07-21T13:11:30.000ZPharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and morehttps://www.pharmaradar360.com/article/nektar-therapeutics-announces-start-of-phase-3-zenith-ad-program-evaluating-nove-1517c5e2f04506ddPharma Surgeen2026-07-21T13:09:44.000ZNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitishttps://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-to-present-and-plan-phase-3-ncp-trial-c60cab6b61aa9e08Pharma Surgeen2026-07-21T13:00:47.000ZOKYO Pharma (Nasdaq: OKYO) to present and plan Phase 3 NCP trialhttps://www.pharmaradar360.com/article/domperidone-new-contraindication-in-patients-with-phaeochromocytoma-due-to-the-r-5960dedb03d84cedPharma Surgeen2026-07-21T13:00:37.000ZDomperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertensionhttps://www.pharmaradar360.com/article/ukhsa-spend-over-500-2026-45a3f0a33e5a8499Pharma Surgeen2026-07-21T12:57:22.000ZUKHSA spend over £500: 2026https://www.pharmaradar360.com/article/boletin-del-comite-de-medicamentos-de-uso-humano-junio-de-2026-8431cf96ceb6628aPharma Surgeen2026-07-21T12:54:11.000ZBoletín del Comité de Medicamentos de Uso Humano. Junio de 2026https://www.pharmaradar360.com/article/boletin-del-comite-de-medicamentos-de-uso-humano-mayo-de-2026-9f27a607b2f0a8dePharma Surgeen2026-07-21T12:52:00.000ZBoletín del Comité de Medicamentos de Uso Humano. Mayo de 2026https://www.pharmaradar360.com/article/danaher-s-revenue-outlook-cut-biotech-miss-overshadow-profit-forecast-raise-ae91a6cc91961d18Pharma Surgeen2026-07-21T12:51:59.000ZDanaher’s revenue outlook cut, biotech miss overshadow profit forecast raisehttps://www.pharmaradar360.com/article/intelligent-bio-solutions-completes-precision-testing-for-fda-510-k-submission-o-2ceac15089453745Pharma Surgeen2026-07-21T12:44:00.000ZIntelligent Bio Solutions Completes Precision Testing for FDA 510(k) Submission of Fingerprint Drug Screening System for Codeine Detectionhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-8101a04f96861ddaPharma Surgeen2026-07-21T12:39:07.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/israeli-polypid-signs-320-million-deal-to-sell-drug-preventing-surgical-infectio-1e3d88587ebf4d51Pharma Surgeen2026-07-21T12:35:49.000ZIsraeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canadahttps://www.pharmaradar360.com/article/biotech-ipo-gains-crush-ai-listings-with-standout-55-return-bc5d34b90f0c0941Pharma Surgeen2026-07-21T12:35:25.000ZBiotech IPO Gains Crush AI Listings With Standout 55% Returnhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-f5c15ae2f615e09ePharma Surgeen2026-07-21T12:35:13.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-stock-slides-20-with-a-9-day-losing-spree-80723ea97764a35dPharma Surgeen2026-07-21T12:33:45.000ZUltragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spreehttps://www.pharmaradar360.com/article/fingerprint-drug-screen-shows-repeatable-results-in-1-600-tests-d19876ed8f88366ePharma Surgeen2026-07-21T12:30:00.000ZFingerprint Drug Screen Shows Repeatable Results in 1,600 Testshttps://www.pharmaradar360.com/article/agios-says-adios-to-sickle-cell-program-over-lackluster-data-c24b4ba8e9adf17aPharma Surgeen2026-07-21T12:30:00.000ZAgios says adios to sickle cell program over lackluster datahttps://www.pharmaradar360.com/article/fda-approves-msd-s-lipfendra-as-first-oral-pcsk9-inhibitor-526f87b7cfbb80f1Pharma Surgeen2026-07-21T12:27:18.000ZFDA approves MSD’s Lipfendra as first oral PCSK9 inhibitorhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-80ef801065e7ad02Pharma Surgeen2026-07-21T12:17:01.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-abril-de-2026-0bf2a64f4466830dPharma Surgeen2026-07-21T12:16:32.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Abril de 2026https://www.pharmaradar360.com/article/pharmather-partners-with-ketamist-inventor-to-accelerate-fda-approval-of-needle-cda1c432d6822b79Pharma Surgeen2026-07-21T12:14:05.000ZPharmaTher Partners with KetaMist Inventor to Accelerate FDA Approval of Needle-Free Ketamine Therapyhttps://www.pharmaradar360.com/article/boletin-sobre-medicamentos-veterinarios-abril-junio-2026-02a9ba07952fe167Pharma Surgeen2026-07-21T12:14:04.000ZBoletín sobre Medicamentos Veterinarios. Abril- Junio 2026https://www.pharmaradar360.com/article/opinion-the-fda-s-505-b-2-pathway-is-an-underestimated-engine-of-value-creation-8f12728fe3a9886ePharma Surgeen2026-07-21T12:12:16.000ZOpinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creationhttps://www.pharmaradar360.com/article/lilly-s-2-8-billion-bet-on-psychedelics-buys-science-that-conventional-trial-inf-68558c0d8002e981Pharma Surgeen2026-07-21T12:08:54.000ZLilly’s $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Runhttps://www.pharmaradar360.com/article/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-in-adjunct-672e53d9f6ba05e1Pharma Surgeen2026-07-21T12:08:08.000ZHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedulehttps://www.pharmaradar360.com/article/shimadzu-x-ray-high-voltage-generators-6fb0dddc89d347e3Pharma Surgeen2026-07-21T12:00:00.000ZShimadzu X-ray High Voltage Generatorshttps://www.pharmaradar360.com/article/mequ-a-s-om-warmer-leakage-0162fc45f38065fdPharma Surgeen2026-07-21T12:00:00.000ZMequ A/S ºM Warmer Leakagehttps://www.pharmaradar360.com/article/verrica-deal-could-bring-ycanth-to-israeli-children-if-approved-5e4874018ce09e11Pharma Surgeen2026-07-21T12:00:00.000ZVerrica deal could bring YCANTH to Israeli children if approvedhttps://www.pharmaradar360.com/article/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-37b3f8159927e1f6Pharma Surgeen2026-07-21T11:56:44.000ZAxiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchangehttps://www.pharmaradar360.com/article/eledon-pharmaceuticals-stock-initiated-at-buy-by-rodman-renshaw-by-investing-com-ef33ab8dfab68846Pharma Surgeen2026-07-21T11:47:39.000ZEledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw By Investing.comhttps://www.pharmaradar360.com/article/cold-spring-biotech-showcases-blood-based-ptau217-test-for-early-alzheimer-s-det-5de516c7be508fd6Pharma Surgeen2026-07-21T11:44:00.000ZCold Spring Biotech Showcases Blood-Based pTau217 Test for Early Alzheimer's Detectionhttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-julio-de-2026-2da2f59b4c1cbb11Pharma Surgeen2026-07-21T11:37:30.000ZReunión del Comité de Medicamentos Veterinarios de julio de 2026https://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-junio-de-2026-780c990bfc3cefdePharma Surgeen2026-07-21T11:35:41.000ZReunión del Comité de Medicamentos Veterinarios de junio de 2026https://www.pharmaradar360.com/article/deprivation-of-liberty-safeguards-england-2025-to-2026-6a53d751c6544f4cPharma Surgeen2026-07-21T11:34:30.000ZDeprivation of Liberty Safeguards, England: 2025 to 2026https://www.pharmaradar360.com/article/jasper-and-kira-merge-to-build-immune-focused-biotech-403454fd208e19f3Pharma Surgeen2026-07-21T11:27:13.000ZJasper and Kira merge to build immune-focused biotechhttps://www.pharmaradar360.com/article/jupiter-neurosciences-nasdaq-juns-signs-definitive-agreement-for-exclusive-u-s-r-ae7a04182b35a4c6Pharma Surgeen2026-07-21T11:26:47.000ZJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Millionhttps://www.pharmaradar360.com/article/summer-registration-exam-pass-rate-highest-since-2021-54bd4f0058a6166fPharma Surgeen2026-07-21T11:10:17.000ZSummer registration exam pass rate highest since 2021https://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-e32e15cb7cc9f78bPharma Surgeen2026-07-21T11:07:45.000ZPharmAla Biotech Executes Definitive License Agreementhttps://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosci-570051b7b34eaa7cPharma Surgeen2026-07-21T11:06:15.000ZPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002https://www.pharmaradar360.com/article/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-7cdf9a33b293e826Pharma Surgeen2026-07-21T11:02:00.000ZAxiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchangehttps://www.pharmaradar360.com/article/there-is-always-a-first-why-us-biotech-axiom-will-begin-its-ipo-journey-in-hong-ab53570559fc3044Pharma Surgeen2026-07-21T11:00:47.000Z‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Konghttps://www.pharmaradar360.com/article/okyo-pharma-chairman-gabriele-cerrone-boosts-stake-to-20-51-with-35-000-share-ac-58e26839372abe6fPharma Surgeen2026-07-21T11:00:11.000ZOKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trialhttps://www.pharmaradar360.com/article/healthcare-ipo-wave-us-biotech-firm-picks-hong-kong-over-nasdaq-for-listing-c803dedff3847054Pharma Surgeen2026-07-21T11:00:09.000ZHealthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listinghttps://www.pharmaradar360.com/article/a-new-era-for-surgery-with-real-time-ai-medtronic-to-unveil-touch-surgerytm-aide-79a9ea28f03da257Pharma Surgeen2026-07-21T11:00:00.000ZA new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026https://www.pharmaradar360.com/article/pbs-biotech-wins-2026-cell-products-development-of-the-year-award-5a7ac13649671983Pharma Surgeen2026-07-21T11:00:00.000ZPBS Biotech Wins 2026 Cell Products Development of the Year Awardhttps://www.pharmaradar360.com/article/pharmala-retains-ala-002-rights-outside-u-s-in-jupiter-license-b48900521d9a8852Pharma Surgeen2026-07-21T11:00:00.000ZPharmAla Retains ALA-002 Rights Outside U.S. in Jupiter Licensehttps://www.pharmaradar360.com/article/compugen-to-hold-1x1-meetings-at-july-28-29-btig-event-e6572d15f8e3f46ePharma Surgeen2026-07-21T11:00:00.000ZCompugen to Hold 1x1 Meetings at July 28-29 BTIG Eventhttps://www.pharmaradar360.com/article/altesa-biosciences-welcomes-seasoned-biotech-leader-brett-haumann-mbbch-mba-as-c-d885bab215f80fefPharma Surgeen2026-07-21T11:00:00.000ZAltesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officerhttps://www.pharmaradar360.com/article/novartis-q2-profits-recover-as-revenue-mantle-passes-to-newer-medicines-a1d1c54b74fc59a3Pharma Surgeen2026-07-21T10:54:56.000ZNovartis Q2 profits recover as revenue mantle passes to newer medicineshttps://www.pharmaradar360.com/article/shaanxi-kanghui-pharmaceutical-s-unit-signs-computing-power-service-contract-0daab72ddc007f7dPharma Surgeen2026-07-21T10:51:28.000ZShaanxi Kanghui Pharmaceutical's Unit Signs Computing Power Service Contracthttps://www.pharmaradar360.com/article/aaic26-alzheimer-s-disease-heterogeneity-calls-for-a-rethink-e927e48702e94fcfPharma Surgeen2026-07-21T10:49:55.000ZAAIC26: Alzheimer’s disease heterogeneity calls for a rethinkhttps://www.pharmaradar360.com/article/us-based-axiom-seeks-hong-kong-ipo-to-tap-china-s-biotech-boom-995709fac9821890Pharma Surgeen2026-07-21T10:45:00.000ZUS-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boomhttps://www.pharmaradar360.com/article/korea-s-kolon-tissuegene-shares-hit-9-month-low-after-knee-therapy-fails-us-phas-85cdea432cb135daPharma Surgeen2026-07-21T10:44:01.000ZKorea’s Kolon TissueGene shares hit 9-month low after knee therapy fails US phase 3 trialhttps://www.pharmaradar360.com/article/arbutus-takes-comirnaty-lnp-patent-fight-to-canada-and-upc-4589edd6afdb085dPharma Surgeen2026-07-21T10:37:55.000ZArbutus takes Comirnaty LNP patent fight to Canada and UPChttps://www.pharmaradar360.com/article/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-d7b92620baddc061Pharma Surgeen2026-07-21T10:28:42.000ZViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026https://www.pharmaradar360.com/article/bristol-myers-nvidia-join-forces-to-build-life-science-s-most-powerful-ai-factor-d5c10f2cf3a6b040Pharma Surgeen2026-07-21T10:14:54.000ZBristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factoryhttps://www.pharmaradar360.com/article/2026-changping-medical-healthcare-financial-investment-innovation-forum-integrat-4c46faeed629f615Pharma Surgeen2026-07-21T10:11:52.000Z2026 Changping Medical & Healthcare Financial Investment Innovation Forum: Integrating Industry Wisdom, Forging Trend-Driven Innovationhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-stock-extends-a-9-day-losing-streak-to-a-20-loss-6f618413c4ca3cd4Pharma Surgeen2026-07-21T10:07:01.000ZUltragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Losshttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-meet-investors-at-btig-biotech-event-832fa4a1deb1c32bPharma Surgeen2026-07-21T10:04:34.000ZAlterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech eventhttps://www.pharmaradar360.com/article/securing-global-pharmaceutical-supply-chains-strategic-redundancy-local-manufact-7a35611e3bfce0adPharma Surgeen2026-07-21T09:39:31.000ZSecuring Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stagehttps://www.pharmaradar360.com/article/swiss-national-bank-buys-941-700-shares-of-teva-pharmaceutical-industries-ltd-te-c0ab44710eb30639Pharma Surgeen2026-07-21T09:23:55.000ZSwiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/jennison-associates-llc-has-43-35-million-position-in-teva-pharmaceutical-indust-c374964c7a992780Pharma Surgeen2026-07-21T09:23:48.000ZJennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-21T09:08:28.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/fda-panel-to-revisit-biden-peptide-ban-as-it-weighs-looser-rules-6f66a3ac9cc29a1ePharma Surgeen2026-07-21T09:05:00.000ZFDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Ruleshttps://www.pharmaradar360.com/article/is-recalled-lettuce-safe-after-false-positive-result-fda-issues-warning-5bbe5766cc6c77adPharma Surgeen2026-07-21T09:00:00.000ZIs recalled lettuce safe after false positive result? FDA issues warninghttps://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-misses-primary-endpoint-in-u-s-trial-stock-hits-limit-do-55bee60e175ac7bePharma Surgeen2026-07-21T08:56:00.000ZKolon TissueGene's TG-C Misses Primary Endpoint in U.S. Trial; Stock Hits Limit Down, Approval Timeline Disruptedhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-rohto-pharmaceutical-co-ltd-tse-4527-0b65e28839ede1b0Pharma Surgeen2026-07-21T08:45:42.000ZEnterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527https://www.pharmaradar360.com/article/hlb-therapeutics-completes-patient-enrollment-in-global-phase-3-trial-of-rgn-259-f2def999a1a3b5f8Pharma Surgeen2026-07-21T08:45:09.000ZHLB Therapeutics completes patient enrollment in global phase 3 trial of RGN-259 for neurotrophic keratitishttps://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-e47569d27763c65bPharma Surgeen2026-07-21T08:41:46.000ZDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientshttps://www.pharmaradar360.com/article/citizens-initiates-annexon-stock-with-underperform-on-ga-trial-concerns-b498e0097c04b512Pharma Surgeen2026-07-21T08:34:00.000ZCitizens initiates Annexon stock with underperform on GA trial concernshttps://www.pharmaradar360.com/article/respiratory-virus-circulation-england-and-wales-3da823e6885aad2aPharma Surgeen2026-07-21T08:30:09.000ZRespiratory virus circulation: England and Waleshttps://www.pharmaradar360.com/article/rabies-risk-assessment-post-exposure-treatment-management-3a1468262bcc50e4Pharma Surgeen2026-07-21T08:30:09.000ZRabies: risk assessment, post-exposure treatment, managementhttps://www.pharmaradar360.com/article/maharashtra-fda-chief-widens-crackdown-on-food-adulteration-fake-drugs-693b78e88c146ca9Pharma Surgeen2026-07-21T08:28:54.000ZMaharashtra FDA chief widens crackdown on food adulteration, fake drugshttps://www.pharmaradar360.com/article/avacta-academy-episode-4-186c0ffcffc3a578Pharma Surgeen2026-07-21T08:19:26.000ZAvacta Academy – Episode 4https://www.pharmaradar360.com/article/field-safety-notices-13-to-17-july-2026-9e5deccdd27e07cbPharma Surgeen2026-07-21T08:16:08.000ZField Safety Notices: 13 to 17 July 2026https://www.pharmaradar360.com/article/ai-healthcare-company-acquires-us-biotech-firm-for-usd-1-7bn-497c6a74207ae1e5Pharma Surgeen2026-07-21T08:06:46.000ZAI healthcare company acquires US biotech firm for USD 1.7bnhttps://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-fails-u-s-phase-3-efficacy-trial-5398516eb35f2d42Pharma Surgeen2026-07-21T08:02:47.000ZKolon TissueGene's TG-C Fails U.S. Phase 3 Efficacy Trialhttps://www.pharmaradar360.com/article/one-of-europe-s-most-advanced-biotech-campuses-is-in-marburg-and-it-s-looking-fo-bf84c83a272727c4Pharma Surgeen2026-07-21T07:52:30.000ZOne of Europe's most advanced biotech campuses is in Marburg — and it's looking for pioneershttps://www.pharmaradar360.com/article/when-bile-acids-tell-a-bigger-story-how-cholestatic-biology-is-reshaping-rare-li-6d2fa66cb53b68e7Pharma Surgeen2026-07-21T07:00:00.000ZWhen bile acids tell a bigger story: how cholestatic biology is reshaping rare liver disease researchhttps://www.pharmaradar360.com/article/4d-molecular-therapeutics-reports-2-year-durability-data-for-4d-150-in-wet-amd-fb62d9ddeeccf32fPharma Surgeen2026-07-21T06:53:30.000Z4D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMDhttps://www.pharmaradar360.com/article/omeicos-omt-28-advances-to-phase-3-trial-in-mitochondrial-disease-1e3397dbb94f14e3Pharma Surgeen2026-07-21T06:53:30.000ZOMEICOS’ OMT-28 Advances to Phase 3 Trial in Mitochondrial Diseasehttps://www.pharmaradar360.com/article/recce-pharmaceuticals-advances-dual-phase-3-programs-and-mena-licensing-strategy-21f730210526ae26Pharma Surgeen2026-07-21T06:47:02.000ZRecce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarterhttps://www.pharmaradar360.com/article/co-ceo-of-kolon-tissuegene-jeon-seung-ho-claimed-that-the-results-of-the-first-p-9de91e145e48ea68Pharma Surgeen2026-07-21T06:04:24.000ZCo-CEO of Kolon TissueGene, Jeon Seung-ho, claimed that the results of the first phase 3 clinical tr..https://www.pharmaradar360.com/article/regional-pharmaceutical-initiative-awarded-16m-in-federal-funds-for-medicine-pro-2308d2852d4633bbPharma Surgeen2026-07-21T06:03:24.000ZRegional pharmaceutical initiative awarded $16M in federal funds for medicine productionhttps://www.pharmaradar360.com/article/biocon-reinforces-commitment-to-diabetes-care-in-malaysia-as-partner-duopharma-b-355d9d554a98c320Pharma Surgeen2026-07-21T05:45:18.000ZBiocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tendershttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-21T05:23:37.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/biotech-deals-surge-to-record-as-fear-of-missing-out-grips-big-pharma-ddccf947efc9f317Pharma Surgeen2026-07-21T05:02:06.000ZBiotech deals surge to record as fear of missing out grips Big Pharmahttps://www.pharmaradar360.com/article/kolon-tissuegene-stumbles-in-us-phase-3-as-placebo-surges-pins-fda-hopes-on-next-0d9829d1b80895ffPharma Surgeen2026-07-21T05:01:00.000ZKolon TissueGene stumbles in US phase 3 as placebo surges, pins FDA hopes on next trial - CHOSUNBIZhttps://www.pharmaradar360.com/article/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-4badd855c4daa1c2Pharma Surgeen2026-07-21T05:00:00.000ZInnate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)https://www.pharmaradar360.com/article/chemical-and-pharmaceutical-industry-half-year-results-for-2026-show-continuing-312df624dc8e8ca7Pharma Surgeen2026-07-21T04:59:15.000ZChemical and pharmaceutical industry: half-year results for 2026 show continuing crisishttps://www.pharmaradar360.com/article/ltr-pharma-secures-national-us-manufacturing-and-fulfilment-partner-0f60d9fe097173b4Pharma Surgeen2026-07-21T04:54:49.000ZLTR Pharma secures national US manufacturing and fulfilment partnerhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-fuso-pharmaceutical-industries-ltd-tse-45-e0e7a3b7a059089ePharma Surgeen2026-07-21T04:32:34.000ZEnterprise value to revenue forward of Fuso Pharmaceutical Industries,Ltd. – TSE:4538https://www.pharmaradar360.com/article/tukaram-mundhe-s-crackdown-working-viral-post-claims-jalebi-has-lost-its-bright-10774273a3a80561Pharma Surgeen2026-07-21T04:30:19.000ZTukaram Mundhe's Crackdown Working? Viral Post Claims Jalebi Has Lost Its Bright Orange Colourhttps://www.pharmaradar360.com/article/world-pharmaceutical-lab-instruments-market-analysis-forecast-size-trends-and-in-9330b37f998fe74aPharma Surgeen2026-07-21T04:26:12.000ZWorld Pharmaceutical Lab Instruments - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/kelun-biotech-announces-phase-iii-study-of-sacituzumab-tirumotecan-sac-tmt-in-co-62461476cf20d1f5Pharma Surgeen2026-07-21T04:11:45.000ZKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpointhttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-21T04:09:57.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/kolon-tissuegene-tg-c-u-s-phase-3-not-a-failure-investigating-unusually-strong-p-a734f7e16ba57973Pharma Surgeen2026-07-21T03:34:14.000ZKolon TissueGene: "TG-C U.S. Phase 3 Not a Failure... Investigating Unusually Strong Placebo Response" (Comprehensive)https://www.pharmaradar360.com/article/shinsa-available-schedule-for-consultation-by-the-office-of-software-as-a-medica-5acbc086921c1ac9Pharma Surgeen2026-07-21T03:00:00.000Z[SHINSA]Available schedule for consultation by the Office of Software as a Medical Device updatedhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-secures-fda-qidp-status-and-expands-phase-3-trial-for-recc-bdfbfa23a5197fb2Pharma Surgeen2026-07-21T02:55:59.000ZRecce Pharmaceuticals Secures FDA QIDP Status and Expands Phase 3 Trial for RECCE® 327 Gel, Advancing Commercial Launch Planshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-advances-recce-327-toward-commercialisation-with-qidp-desi-32b445ed32902788Pharma Surgeen2026-07-21T02:55:59.000ZRecce Pharmaceuticals Advances RECCE® 327 Toward Commercialisation With QIDP Designation and Phase 3 Indonesian Trial Expansionhttps://www.pharmaradar360.com/article/south-korea-eases-biosimilar-phase-3-trial-rules-54a0295ab47c524dPharma Surgeen2026-07-21T02:43:56.000ZSouth Korea Eases Biosimilar Phase 3 Trial Ruleshttps://www.pharmaradar360.com/article/gates-medical-research-institute-and-the-serum-institute-of-india-reach-agreemen-05d2c34a9bf56fa6Pharma Surgeen2026-07-21T02:41:38.000ZGates Medical Research Institute and the Serum Institute of India reach agreement for the manufacture of M72/AS01E TB vaccine candidate, pending successful Phase 3 outcomeshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-expands-mena-reach-with-exclusive-distribution-deal-and-ad-6cb51036a442bf81Pharma Surgeen2026-07-21T02:33:06.000ZRecce Pharmaceuticals Expands MENA Reach with Exclusive Distribution Deal and Advances Diabetic Foot Infection Treatment to Phase 3https://www.pharmaradar360.com/article/recce-pharmaceuticals-secures-middle-east-distribution-deal-and-advances-diabeti-d7e00ac40a89b4dcPharma Surgeen2026-07-21T02:33:06.000ZRecce Pharmaceuticals Secures Middle East Distribution Deal and Advances Diabetic Foot Infection Clinical Trial to Phase 3https://www.pharmaradar360.com/article/the-stock-price-fell-to-the-price-limit-on-the-news-that-kolon-tissuegene-did-no-5f19d9c535cb66f5Pharma Surgeen2026-07-21T02:30:34.000ZThe stock price fell to the price limit on the news that Kolon TissueGene did not get the expected r..https://www.pharmaradar360.com/article/the-first-pharmaceutical-company-to-deploy-nvidia-s-vera-rubin-has-arrived-drug-a1645fd5ee579687Pharma Surgeen2026-07-21T02:20:08.000ZThe first pharmaceutical company to deploy NVIDIA’s Vera Rubin has arrived! Drug development timelines could be shortened by 50%.https://www.pharmaradar360.com/article/u-k-cabinet-shuffle-taiwan-biotech-and-biogen-data-a-biocentury-podcast-f7cd6b2907dc4274Pharma Surgeen2026-07-21T02:08:00.000ZU.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcasthttps://www.pharmaradar360.com/article/most-wanted-fugitive-hid-out-for-21-years-as-a-biotech-exec-d8364014b7d3da7cPharma Surgeen2026-07-21T02:00:00.000ZMost-Wanted Fugitive Hid Out For 21 Years As A Biotech Exechttps://www.pharmaradar360.com/article/de-risking-a-rare-disease-launch-starts-with-precision-6be3f3847ba51414Pharma Surgeen2026-07-21T01:58:03.000ZDe-Risking a Rare Disease Launch Starts with Precisionhttps://www.pharmaradar360.com/article/building-a-transformative-career-across-academia-advocacy-and-biotech-karen-knud-437cd8f9d3820611Pharma Surgeen2026-07-21T01:55:47.000ZBuilding a Transformative Career Across Academia, Advocacy, and Biotech - Karen Knudsenhttps://www.pharmaradar360.com/article/kolon-tissuegene-us-phase-3-trial-of-tg-c-is-a-half-success-not-a-failure-5410d1ee58b23309Pharma Surgeen2026-07-21T01:44:13.000ZKolon TissueGene: "US Phase 3 Trial of TG-C Is a Half-Success, Not a Failure"https://www.pharmaradar360.com/article/mizuho-reiterates-acadia-stock-rating-on-alzheimer-s-trial-progress-30faf17c2e556e70Pharma Surgeen2026-07-21T01:39:44.000ZMizuho reiterates Acadia stock rating on Alzheimer’s trial progresshttps://www.pharmaradar360.com/article/rhode-island-fugitive-captured-after-20-years-was-running-biotech-company-in-la-400bfeb14b9f2ad2Pharma Surgeen2026-07-21T01:37:16.000ZRhode Island fugitive captured after 20 years was running biotech company in LAhttps://www.pharmaradar360.com/article/biosimilar-phase-3-waivers-a-boon-for-big-pharma-a-new-hurdle-for-smaller-player-f91f7faf71fa862fPharma Surgeen2026-07-21T01:15:00.000ZBiosimilar Phase 3 Waivers: A Boon for Big Pharma, a New Hurdle for Smaller Playershttps://www.pharmaradar360.com/article/beyond-forecasting-how-synthetic-cohort-simulation-could-reshape-pharmaceutical-4bd294f4c13342e8Pharma Surgeen2026-07-21T00:59:04.000ZBeyond Forecasting: How Synthetic Cohort Simulation Could Reshape Pharmaceutical Commercial Planninghttps://www.pharmaradar360.com/article/rhode-island-fugitive-captured-after-20-years-was-running-biotech-company-in-la-7524652fcc55784dPharma Surgeen2026-07-21T00:32:49.000ZRhode Island fugitive captured after 20 years was running biotech company in LAhttps://www.pharmaradar360.com/article/establishing-a-national-programme-for-guideline-adaptation-key-steps-and-functio-07cb96f265da144dPharma Surgeen2026-07-21T00:00:00.000ZEstablishing a national programme for guideline adaptation: key steps and functionshttps://www.pharmaradar360.com/article/who-global-traditional-medicine-centre-annual-report-2025-567f61197d05325dPharma Surgeen2026-07-21T00:00:00.000ZWHO Global Traditional Medicine Centre: Annual Report 2025https://www.pharmaradar360.com/article/sfda-suspends-registration-of-drug-tavneos-avacopan-8252b1c46f96856bPharma Surgeen2026-07-21T00:00:00.000ZSFDA Suspends Registration of Drug Tavneos (avacopan)https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-8cb289f07818aa1fPharma Surgeen2026-07-21T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/novartis-filed-form-6-k-20a1ac3d4d2b61dePharma Surgeen2026-07-21T00:00:00.000ZNovartis filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-88df047f8efad874Pharma Surgeen2026-07-21T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-2f78cdbfc105c32dPharma Surgeen2026-07-21T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-14d91a52a807bb23Pharma Surgeen2026-07-21T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5b918c5cf06ff809Pharma Surgeen2026-07-21T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9258570721e2d233Pharma Surgeen2026-07-21T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-c5c97cb3ea77888ePharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-04b102a58c35f16fPharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-5e6a2428a7c89ca1Pharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-545126e2717886a7Pharma Surgeen2026-07-21T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c8ba74b6ae3c40e0Pharma Surgeen2026-07-21T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-bd0bc199ca69e8dfPharma Surgeen2026-07-21T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-c1b67cd3fd157ba5Pharma Surgeen2026-07-21T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-afe46bba8c38e81dPharma Surgeen2026-07-21T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-7b2dd2f255a750b4Pharma Surgeen2026-07-21T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-21T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/investigational-once-weekly-oral-hiv-treatment-regimen-of-islatravir-and-lenacap-cc1b9e8bf0b43515Pharma Surgeen2026-07-21T00:00:00.000ZInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapyhttps://www.pharmaradar360.com/article/gilead-to-present-new-hiv-research-at-aids-2026-across-prevention-treatment-and-9a42ab66d1f65212Pharma Surgeen2026-07-21T00:00:00.000ZGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Curehttps://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-hhs-notice-of-benefit-and-payment-par-cc8c1ac89391b82fPharma Surgeen2026-07-21T00:00:00.000ZPatient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correctionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-c5ae6a9f7c082883Pharma Surgeen2026-07-21T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-extensi-6c897bb4af01a5ecPharma Surgeen2026-07-21T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Periodhttps://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-meeting-9ba7dc36d4c23e00Pharma Surgeen2026-07-21T00:00:00.000ZNational Institute of Neurological Disorders and Stroke; Notice of Meetinghttps://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-subcommittee-for-pr-4c2f7f7d38b10efbPharma Surgeen2026-07-21T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/recharter-for-the-advisory-commission-on-childhood-vaccines-ecd86327be462cfdPharma Surgeen2026-07-21T00:00:00.000ZRecharter for the Advisory Commission on Childhood Vaccineshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-temporary-assistance-for-n-39a6e356c0618e99Pharma Surgeen2026-07-21T00:00:00.000ZSubmission for Office of Management and Budget Review; Temporary Assistance for Needy Families (TANF) Financial Report, ACF-196Thttps://www.pharmaradar360.com/article/emergency21-july-2026-feature-storyuganda-safeguards-essential-health-services-d-1b1e494292ff29c3Pharma Surgeen2026-07-21T00:00:00.000ZEmergency21 July 2026 Feature StoryUganda safeguards essential health services during Ebola outbreak responsehttps://www.pharmaradar360.com/article/haslam-family-makes-25-million-investment-to-support-cleveland-clinic-s-continue-0a294129dc60aee6Pharma Surgeen2026-07-21T00:00:00.000ZHaslam Family Makes $25 Million Investment to Support Cleveland Clinic's Continued Growth and Impacthttps://www.pharmaradar360.com/article/clinicopathological-spectrum-of-buccal-mucosal-lipomas-a-report-of-two-case-34cef0a4d727c575Pharma Surgeen2026-07-21T00:00:00.000ZClinicopathological Spectrum of Buccal Mucosal Lipomas: A Report of Two-Casehttps://www.pharmaradar360.com/article/evaluating-the-impact-of-the-malaria-vaccine-rollout-on-malaria-morbidity-among-aaa2f6b696ebc740Pharma Surgeen2026-07-21T00:00:00.000ZEvaluating the Impact of the Malaria Vaccine Rollout on Malaria Morbidity Among Under-Five Children in Phase 1 MVIP Districts in Oti Region, Ghanahttps://www.pharmaradar360.com/article/lessons-learned-through-transitioning-into-a-clinical-research-nurse-role-a-refl-098ad6f99c27c07aPharma Surgeen2026-07-21T00:00:00.000ZLessons learned through transitioning into a clinical research nurse role: a reflective practice accounthttps://www.pharmaradar360.com/article/effectiveness-of-cryotherapy-cooling-gel-pack-on-procedural-pain-and-distress-du-3202b8a2890d2708Pharma Surgeen2026-07-21T00:00:00.000ZEffectiveness of Cryotherapy (Cooling Gel Pack) on Procedural Pain and Distress During Chest Tube Removal Post-Coronary Artery Bypass Graft (CABG) Surgery: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-and-cerebrospinal-fluid-predictors-of-sensorineural-hearing-loss-in-adu-9c430e31e3486242Pharma Surgeen2026-07-21T00:00:00.000ZClinical and Cerebrospinal Fluid Predictors of Sensorineural Hearing Loss in Adults with Acute Bacterial Meningitis: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/insulin-resistance-among-adults-with-type-2-diabetes-an-observational-study-46dbce5828c96a5bPharma Surgeen2026-07-21T00:00:00.000ZInsulin Resistance Among Adults with Type 2 Diabetes — an Observational Studyhttps://www.pharmaradar360.com/article/war-as-an-evolutionary-accelerator-of-antimicrobial-resistance-environmental-cli-f493fd4a440df4f7Pharma Surgeen2026-07-21T00:00:00.000ZWar as an evolutionary accelerator of antimicrobial resistance: environmental, clinical, veterinary, and political drivers in modern conflict zoneshttps://www.pharmaradar360.com/article/prevalence-and-correlation-between-dental-fluorosis-and-drinking-water-fluoride-2f11d7630c291400Pharma Surgeen2026-07-21T00:00:00.000ZPrevalence and Correlation between Dental Fluorosis and Drinking Water Fluoride Levels among 12–15-year-old School-going Children of Rayalaseema Region of Andhra Pradesh, Indiahttps://www.pharmaradar360.com/article/comparative-evaluation-of-pain-perception-following-topical-application-of-clove-81242a2fb1367d36Pharma Surgeen2026-07-21T00:00:00.000ZComparative Evaluation of Pain Perception Following Topical Application of Clove Oil, EMLA 5%, and Lignocaine Hydrochloride Gel 2% as a Pre-anesthetic Agent in Children Aged 7–10 Years: A Randomized Controlled Studyhttps://www.pharmaradar360.com/article/pain-alleviation-by-electronic-acupuncture-pen-versus-ethyl-chloride-spray-durin-e07830458a96d531Pharma Surgeen2026-07-21T00:00:00.000ZPain Alleviation by Electronic Acupuncture Pen versus Ethyl Chloride Spray during Local Anesthetic Injection Procedures: A Randomized Split-mouth Clinical Trialhttps://www.pharmaradar360.com/article/oral-embryonal-rhabdomyosarcoma-and-its-management-a-rare-enigmatic-pediatric-ca-b3a50989b96be3d3Pharma Surgeen2026-07-21T00:00:00.000ZOral Embryonal Rhabdomyosarcoma and Its Management: A Rare Enigmatic Pediatric Case Report with Immunohistochemistryhttps://www.pharmaradar360.com/article/evaluating-the-correlation-between-iq-and-behavior-of-5-10-year-old-children-in-b22e93affcf3712fPharma Surgeen2026-07-21T00:00:00.000ZEvaluating the Correlation between IQ and Behavior of 5–10-year-old Children in Dental Operatory: A Cross-sectional Studyhttps://www.pharmaradar360.com/article/nature-s-cross-linkers-in-vitro-evaluation-of-proanthocyanidin-rich-agents-on-ad-9d932e2678a1bfd9Pharma Surgeen2026-07-21T00:00:00.000ZNature\'s Cross-linkers: In Vitro Evaluation of Proanthocyanidin-rich Agents on Adhesive Bond Strengthhttps://www.pharmaradar360.com/article/analytical-review-small-intestinal-bacterial-overgrowth-syndrome-in-clinical-pra-3b7b6e0d7aaed97cPharma Surgeen2026-07-21T00:00:00.000ZAnalytical Review: Small Intestinal Bacterial Overgrowth Syndrome in Clinical Practicehttps://www.pharmaradar360.com/article/bridging-clinical-severity-and-cognitive-flexibility-a-mediation-analysis-of-emo-a3e10fa12e4df773Pharma Surgeen2026-07-21T00:00:00.000ZBridging Clinical Severity and Cognitive Flexibility: A Mediation Analysis of Emotion Regulation in Affective Disordershttps://www.pharmaradar360.com/article/retraction-didehydrosuberoylanilide-hydroxamic-acid-ddsaha-as-precursor-and-poss-5a5f6a4974f1bfacPharma Surgeen2026-07-21T00:00:00.000ZRetraction: α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHAhttps://www.pharmaradar360.com/article/clinical-evaluation-of-bevacizumab-intravenous-infusion-associated-bleeding-risk-461d4775ebf51c82Pharma Surgeen2026-07-21T00:00:00.000ZClinical evaluation of bevacizumab intravenous infusion–associated bleeding risk and vascular stress under a vascular protective management pathway in recurrent ovarian cancerhttps://www.pharmaradar360.com/article/berberine-ameliorates-doxorubicin-induced-cardiac-toxicity-via-regulation-of-the-0ac635a642a246a9Pharma Surgeen2026-07-21T00:00:00.000ZBerberine ameliorates doxorubicin-induced cardiac toxicity via regulation of the SNHG14/miR-9-5p/PDK4 axishttps://www.pharmaradar360.com/article/effect-of-ultrasound-guided-sciatic-and-saphenous-nerve-blocks-on-analgesia-duri-7f598236746d6a33Pharma Surgeen2026-07-21T00:00:00.000ZEffect of Ultrasound-Guided Sciatic and Saphenous Nerve Blocks on Analgesia During General Anaesthesia for Ankle Fracture Surgery: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/laparoscopic-fundoplication-using-the-excluded-stomach-versus-conversion-to-roux-fc2bd960558d9d59Pharma Surgeen2026-07-21T00:00:00.000ZLaparoscopic Fundoplication Using the Excluded Stomach Versus Conversion to Roux-en-Y Gastric Bypass for Refractory Reflux After One-Anastomosis Gastric Bypass: A Retrospective Comparative Analysis of Safety and 1-Year Outcomeshttps://www.pharmaradar360.com/article/clopidogrel-versus-prasugrel-versus-ticagrelor-in-patients-with-acute-coronary-s-5e82c1c49415cf34Pharma Surgeen2026-07-21T00:00:00.000ZClopidogrel Versus Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome: New Insights from a Large Registry Compared to Randomized Clinical Trials—A Structured Reviewhttps://www.pharmaradar360.com/article/time-in-range-and-adverse-outcomes-in-type-2-diabetes-a-quantitative-synthesis-10ce5e77abaee81ePharma Surgeen2026-07-21T00:00:00.000ZTime in Range and Adverse Outcomes in Type 2 Diabetes: A Quantitative Synthesishttps://www.pharmaradar360.com/article/risk-factors-for-postoperative-complications-in-hallux-valgus-surgery-a-retrospe-6dff5f6ad792967fPharma Surgeen2026-07-21T00:00:00.000ZRisk Factors for Postoperative Complications in Hallux Valgus Surgery: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/evolution-of-friedreich-s-ataxia-management-across-established-and-emerging-ther-911057e7a65e5f55Pharma Surgeen2026-07-21T00:00:00.000ZEvolution of Friedreich’s Ataxia Management Across Established and Emerging Therapies—Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/antiplatelet-therapy-for-stroke-prevention-in-atherosclerotic-cardiovascular-dis-ea0ad1ae8cc5b23aPharma Surgeen2026-07-21T00:00:00.000ZAntiplatelet Therapy for Stroke Prevention in Atherosclerotic Cardiovascular Disease-Naïve People with Cerebral Small-Vessel Disease: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/functional-and-structural-outcomes-of-photodynamic-therapy-pdt-with-or-without-e-6063eb899e8cc5a3Pharma Surgeen2026-07-21T00:00:00.000ZFunctional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathyhttps://www.pharmaradar360.com/article/clinical-obesity-and-insulin-resistance-assessed-based-on-shbg-levels-and-homa-i-28afe024a468a1aaPharma Surgeen2026-07-21T00:00:00.000ZClinical Obesity and Insulin Resistance Assessed Based on SHBG Levels and HOMA-IR, TyG-Waist Circumference (TyG-WC), TyG-Waist to Height Ratio (TyG-WHtR), and TyG-Waist to Hip Ratio (TyG-WHR) Values in Young Caucasian Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS)https://www.pharmaradar360.com/article/carotid-plaques-and-type-2-diabetes-as-predictors-of-cardiovascular-events-and-m-a701fa1868e87831Pharma Surgeen2026-07-21T00:00:00.000ZCarotid Plaques and Type 2 Diabetes as Predictors of Cardiovascular Events and Mortality: Insights from the LitHiR Prospective Cohort Studyhttps://www.pharmaradar360.com/article/the-5-2-diet-reduces-risk-factors-for-cardiovascular-disease-in-subjects-with-an-265f6cafee96d3ffPharma Surgeen2026-07-21T00:00:00.000ZThe 5:2 Diet Reduces Risk Factors for Cardiovascular Disease in Subjects with and Without Type 2 Diabetes—A Non-Randomized Controlled Trialhttps://www.pharmaradar360.com/article/influence-of-genetic-polymorphisms-on-omalizumab-clinical-response-in-pediatric-4493b242d6d78641Pharma Surgeen2026-07-21T00:00:00.000ZInfluence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot studyhttps://www.pharmaradar360.com/article/picu-diaries-and-parental-ptsd-symptoms-a-pilot-randomized-controlled-trial-asse-797e4e00c11bc21cPharma Surgeen2026-07-21T00:00:00.000ZPICU diaries and parental PTSD symptoms—a pilot randomized controlled trial assessing feasibility and psychological outcomeshttps://www.pharmaradar360.com/article/editorial-advances-in-neuromodulation-for-chronic-pain-mechanisms-and-clinical-i-18b78a4edc1cb286Pharma Surgeen2026-07-21T00:00:00.000ZEditorial: Advances in neuromodulation for chronic pain: mechanisms and clinical implicationshttps://www.pharmaradar360.com/article/clinical-efficacy-of-repetitive-transcranial-magnetic-stimulation-combined-with-2e575b39d322730cPharma Surgeen2026-07-21T00:00:00.000ZClinical efficacy of repetitive transcranial magnetic stimulation combined with electroacupuncture at Baliao points for functional constipation: a retrospective studyhttps://www.pharmaradar360.com/article/prognostic-analysis-of-first-recurrence-metastasis-esophageal-squamous-cell-carc-164c1c0cc633febdPharma Surgeen2026-07-21T00:00:00.000ZPrognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategieshttps://www.pharmaradar360.com/article/possible-wound-healing-potential-and-ethnopharmacological-profiling-of-solvent-f-c3ac9c5084a4dbefPharma Surgeen2026-07-21T00:00:00.000ZPossible Wound Healing Potential and Ethnopharmacological Profiling of Solvent-Fractionated Stem Extracts of Tinospora cordifolia: a Comparative Study with Marketed Dosage Forms in Bangladeshhttps://www.pharmaradar360.com/article/preparation-and-evaluation-of-repaglinide-loaded-liposomes-via-thin-film-hydrati-de1d0b44ae5fb47aPharma Surgeen2026-07-21T00:00:00.000ZPreparation and Evaluation of Repaglinide-Loaded Liposomes via Thin Film Hydration: Impact of Excipients on Formulation Propertieshttps://www.pharmaradar360.com/article/development-and-characterization-of-plant-mediated-silver-nanoparticles-incorpor-d6e1f96823b84f29Pharma Surgeen2026-07-21T00:00:00.000ZDevelopment and Characterization of Plant-Mediated Silver Nanoparticles Incorporating Semecarpus anacardium Extracthttps://www.pharmaradar360.com/article/an-optimized-cad-framework-for-ct-based-knee-joint-reconstruction-984cd1c8a95d1a51Pharma Surgeen2026-07-21T00:00:00.000ZAn Optimized CAD Framework for CT-Based Knee Joint Reconstructionhttps://www.pharmaradar360.com/article/effect-of-a-folklore-powder-on-hyperglyacemic-rats-in-comparison-with-glibenclam-22b543903f139cb2Pharma Surgeen2026-07-21T00:00:00.000ZEFFECT OF A FOLKLORE POWDER ON HYPERGLYACEMIC RATS IN COMPARISON WITH GLIBENCLAMIDEhttps://www.pharmaradar360.com/article/emerging-role-of-multi-omics-approaches-in-tumor-classification-263f8bfa827d77d6Pharma Surgeen2026-07-21T00:00:00.000ZEMERGING ROLE OF MULTI-OMICS APPROACHES IN TUMOR CLASSIFICATIONhttps://www.pharmaradar360.com/article/phytochemical-profiling-in-silico-screening-and-antiinflammatory-evaluation-of-b-5226943bfee4ab66Pharma Surgeen2026-07-21T00:00:00.000ZPhytochemical Profiling, In Silico Screening And AntiInflammatory Evaluation Of Bioactive Compounds From Larrea Tridentatahttps://www.pharmaradar360.com/article/do-plaque-disclosing-tablets-improve-oral-hygiene-in-patients-with-bonded-lingua-caee563036faae27Pharma Surgeen2026-07-21T00:00:00.000ZDo plaque-disclosing tablets improve oral hygiene in patients with bonded lingual retainers - a randomized controlled clinical trial?https://www.pharmaradar360.com/article/large-radicular-cyst-associated-with-a-deciduous-tooth-a-rare-clinical-challenge-4280f8c0a7a8bd99Pharma Surgeen2026-07-21T00:00:00.000ZLarge Radicular Cyst Associated with a Deciduous Tooth: A Rare Clinical Challengehttps://www.pharmaradar360.com/article/wearable-biosensors-for-early-detection-of-clinical-deterioration-a-clinical-par-a7226bc6dc36e946Pharma Surgeen2026-07-21T00:00:00.000ZWearable Biosensors for Early Detection of Clinical Deterioration: A Clinical Paradigm Shift from Episodic Snapshot Screening to Continuous AI-Driven Predictive Surveillancehttps://www.pharmaradar360.com/article/studying-the-effect-of-scrophularia-striata-extract-on-the-improvement-of-recurr-9e0da43b6f5ca9bePharma Surgeen2026-07-21T00:00:00.000ZStudying the effect of Scrophularia striata extract on the improvement of recurrent oral ulcers: A clinical trial studyhttps://www.pharmaradar360.com/article/severity-levels-of-dsm-5-somatic-symptom-disorder-in-medical-inpatients-assessin-8779479b08a2c622Pharma Surgeen2026-07-21T00:00:00.000ZSeverity levels of DSM-5 somatic symptom disorder in medical inpatients: assessing clinical relevance in a cross-sectional samplehttps://www.pharmaradar360.com/article/clinical-applications-and-advances-in-noninvasive-prognostic-assessment-of-metab-068450c4997755bcPharma Surgeen2026-07-21T00:00:00.000ZClinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver diseasehttps://www.pharmaradar360.com/article/clinical-case-of-acute-formation-and-rupture-of-cerebral-aneurysm-in-a-patient-w-c2f04564e3b5269dPharma Surgeen2026-07-21T00:00:00.000ZClinical case of acute formation and rupture of cerebral aneurysm in a patient with autoimmune encephalitishttps://www.pharmaradar360.com/article/comparative-pharmacoeconomic-analysis-of-sequential-treatment-lines-for-advanced-ade9ec0c0ea7eb5dPharma Surgeen2026-07-21T00:00:00.000ZComparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice studyhttps://www.pharmaradar360.com/article/impact-of-antihypertensive-drugs-on-male-fertility-mechanistic-insights-from-exp-cbe3d6f52264b2ccPharma Surgeen2026-07-21T00:00:00.000ZImpact of antihypertensive drugs on male fertility: mechanistic insights from experimental and clinical evidencehttps://www.pharmaradar360.com/article/direct-analysis-of-transcription-factor-protected-cfdna-in-plasma-by-chip-seq-me-4a4450a463c04d03Pharma Surgeen2026-07-21T00:00:00.000ZDirect analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsyhttps://www.pharmaradar360.com/article/action-observation-therapy-in-pediatric-cerebral-palsy-an-fnirs-based-investigat-29e94cb73e4f54ffPharma Surgeen2026-07-21T00:00:00.000ZAction observation therapy in pediatric cerebral palsy: an fNIRS-based investigation of cortical responses and balance—a randomized controlled trialhttps://www.pharmaradar360.com/article/accelerated-recovery-and-alleviated-pain-by-oral-whey-protein-in-herpes-zoster-p-2fa3372d49278ec2Pharma Surgeen2026-07-21T00:00:00.000ZAccelerated recovery and alleviated pain by oral whey protein in herpes zoster patients: a randomized controlled trialhttps://www.pharmaradar360.com/article/impact-of-structured-refresher-training-on-clinical-competence-of-primary-health-b9418ac8e841c681Pharma Surgeen2026-07-21T00:00:00.000ZImpact of structured refresher training on clinical competence of primary healthcare nurses in Karachi, Pakistan: a quasi-experimental studyhttps://www.pharmaradar360.com/article/a-predictive-model-for-recurrence-after-hysteroscopic-endometrial-polypectomy-a-9ad2e1f4376552d7Pharma Surgeen2026-07-21T00:00:00.000ZA predictive model for recurrence after hysteroscopic endometrial polypectomy: a combined analysis of clinical and ultrasound parametershttps://www.pharmaradar360.com/article/machine-learning-based-clinical-models-for-prediction-of-urinary-incontinence-af-2aeb9332a063c988Pharma Surgeen2026-07-21T00:00:00.000ZMachine learning-based clinical models for prediction of urinary incontinence after robot-assisted laparoscopic radical prostatectomyhttps://www.pharmaradar360.com/article/the-effect-of-a-pregnancy-pillow-used-in-the-last-trimester-on-fatigue-and-comfo-79e4529048ce5ad5Pharma Surgeen2026-07-21T00:00:00.000ZThe effect of a pregnancy pillow used in the last trimester on fatigue and comfort in pregnant women: a randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-square-step-exercise-on-fear-of-falling-in-older-patients-with-ischem-6688d8227a97b6a1Pharma Surgeen2026-07-21T00:00:00.000ZEffects of square-step exercise on fear of falling in older patients with ischemic stroke: a cluster randomized controlled trialhttps://www.pharmaradar360.com/article/zero-shot-large-language-models-for-preliminary-prediction-of-ptsd-symptoms-from-28af72ea6ee09e64Pharma Surgeen2026-07-21T00:00:00.000ZZero-Shot Large Language Models for Preliminary Prediction of PTSD Symptoms From Clinical Interview Transcripts: Grands modèles de langage sans exemple pour la prédiction préliminaire des symptômes de TSPT à partir de transcriptions d'entrevues cliniqueshttps://www.pharmaradar360.com/article/comparative-risks-of-pregnancy-complications-in-women-prescribed-psychostimulant-6733647748bbf53fPharma Surgeen2026-07-21T00:00:00.000ZComparative Risks of Pregnancy Complications in Women Prescribed Psychostimulants or Atomoxetine During Pregnancy Following Pre‐Pregnancy Stimulant Usehttps://www.pharmaradar360.com/article/sirolimus-eluting-balloon-with-provisional-stenting-versus-systematic-drug-eluti-9616b9b6e2fbe808Pharma Surgeen2026-07-21T00:00:00.000ZSirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trialhttps://www.pharmaradar360.com/article/effects-of-a-food-is-medicine-intervention-on-glucose-control-among-medicaid-ins-ee319b395afe3ff3Pharma Surgeen2026-07-21T00:00:00.000ZEffects of a “Food Is Medicine” Intervention on Glucose Control Among Medicaid-Insured Patients With Type 2 Diabetes: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/medication-adherence-in-relation-to-beliefs-about-medicines-and-health-related-q-6fa95b3bbb0e9385Pharma Surgeen2026-07-21T00:00:00.000ZMedication Adherence in Relation to Beliefs About Medicines and Health‐Related Quality of Life Among Community‐Dwelling Patients: A Cross‐Sectional Analysishttps://www.pharmaradar360.com/article/oral-aging-in-older-adults-mechanisms-assessment-and-clinical-relevance-in-gerod-b5d3ec5c5b1cc5b0Pharma Surgeen2026-07-21T00:00:00.000ZOral Aging in Older Adults: Mechanisms, Assessment and Clinical Relevance in Gerodontology: A Narrative Reviewhttps://www.pharmaradar360.com/article/predictors-of-treatment-outcome-for-internet-delivered-cognitive-behavioural-the-670ea5b058892759Pharma Surgeen2026-07-21T00:00:00.000ZPredictors of treatment outcome for internet‐delivered cognitive‐behavioural therapy for individuals with obsessive‐compulsive disorder: A systematic reviewhttps://www.pharmaradar360.com/article/a-randomized-trial-to-increase-outpatient-asthma-referrals-upon-pediatric-emerge-6db50ef9df482f1dPharma Surgeen2026-07-21T00:00:00.000ZA Randomized Trial to Increase Outpatient Asthma Referrals Upon Pediatric Emergency Department Dischargehttps://www.pharmaradar360.com/article/the-dual-role-of-exosomes-in-renal-fibrosis-and-their-potential-for-clinical-tra-ca40054317eb3bb4Pharma Surgeen2026-07-21T00:00:00.000ZThe dual role of exosomes in renal fibrosis and their potential for clinical translational applicationshttps://www.pharmaradar360.com/article/dalpiciclib-plus-endocrine-therapy-in-women-with-hr-her2-advanced-breast-cancer-0baddb7b04ceeddbPharma Surgeen2026-07-21T00:00:00.000ZDalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trialhttps://www.pharmaradar360.com/article/yolo11-based-deep-learning-system-for-automated-tubal-patency-classification-in-4b16d0464652431cPharma Surgeen2026-07-21T00:00:00.000ZYOLO11-based deep learning system for automated tubal patency classification in hysterosalpingography: a comparative study for clinical decision supporthttps://www.pharmaradar360.com/article/biogenic-chitosan-encapsulated-cu-zno-nanocomposite-surface-coating-inhibits-mdr-2a3b61d3c59d7e55Pharma Surgeen2026-07-21T00:00:00.000ZBiogenic chitosan-encapsulated Cu/ZnO nanocomposite surface coating inhibits MDR Pseudomonas aeruginosa biofilm establishment on orthopedic implantshttps://www.pharmaradar360.com/article/coffee-consumption-and-its-association-with-knee-osteoarthritis-a-systematic-rev-c907fc52c3801bcePharma Surgeen2026-07-21T00:00:00.000ZCoffee Consumption and its Association with Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studieshttps://www.pharmaradar360.com/article/investigation-of-payloads-and-related-impurities-in-the-cysteine-linked-antibody-96609bd7a0a2396bPharma Surgeen2026-07-21T00:00:00.000ZInvestigation of Payloads and Related Impurities in the cysteine-linked Antibody-Drug Conjugate Using Mass Spectrometry Techniqueshttps://www.pharmaradar360.com/article/sublingual-cyclobenzaprine-for-fibromyalgia-pharmacokinetic-rationale-clinical-e-81bc81831a21bc33Pharma Surgeen2026-07-21T00:00:00.000ZSublingual Cyclobenzaprine for Fibromyalgia: Pharmacokinetic Rationale, Clinical Evidence, and Place in Therapyhttps://www.pharmaradar360.com/article/sex-disparities-in-autism-spectrum-disorder-among-adolescents-in-the-western-pac-e0745f0c17d6dd3cPharma Surgeen2026-07-21T00:00:00.000ZSex Disparities in Autism Spectrum Disorder Among Adolescents in the Western Pacific Region: Insights From Epidemiological Trends and Clinical Samplehttps://www.pharmaradar360.com/article/expression-of-vista-on-peripheral-blood-mononuclear-cells-in-systemic-lupus-eryt-bd665236e494c9c4Pharma Surgeen2026-07-21T00:00:00.000ZExpression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment statushttps://www.pharmaradar360.com/article/association-between-areds-2-supplementation-and-structural-and-functional-progre-19b461547b59f127Pharma Surgeen2026-07-21T00:00:00.000ZAssociation between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2https://www.pharmaradar360.com/article/robustness-of-automated-bruch-s-membrane-opening-minimum-rim-width-and-retinal-n-0255a54d20ee6948Pharma Surgeen2026-07-21T00:00:00.000ZRobustness of automated Bruch’s membrane opening minimum rim width and retinal nerve fiber layer thickness without clinical disc margin adjustment in glaucomahttps://www.pharmaradar360.com/article/lidar-registered-freehand-spect-combined-with-nir-fluorescence-enables-spatial-l-2fc4e88be3efb10fPharma Surgeen2026-07-21T00:00:00.000ZLiDAR-registered freehand SPECT combined with NIR-fluorescence enables spatial localisation of tracer-avid inguinal lymph nodes: A clinical feasibility studyhttps://www.pharmaradar360.com/article/can-we-trust-llms-for-medical-diagnosis-evaluating-robustness-of-clinical-reason-f483dc45977c1cb5Pharma Surgeen2026-07-21T00:00:00.000ZCan We Trust LLMs for Medical Diagnosis? Evaluating Robustness of Clinical Reasoning Under Perturbationhttps://www.pharmaradar360.com/article/neurologic-manifestations-of-long-scp-covid-scp-affect-adult-females-more-severe-2a5c694e11d01fcfPharma Surgeen2026-07-21T00:00:00.000ZNeurologic Manifestations of Long <scp>COVID</scp> Affect Adult Females More Severely Than Maleshttps://www.pharmaradar360.com/article/finerenone-in-patients-with-chronic-kidney-disease-due-to-glomerular-diseases-2fb90a22f0f72a2aPharma Surgeen2026-07-21T00:00:00.000ZFinerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseaseshttps://www.pharmaradar360.com/article/nct07718334-impact-of-a-mobile-application-based-medication-reminder-on-treatmen-66e007c0734604c4Pharma Surgeen2026-07-21T00:00:00.000ZNCT07718334: Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspectivehttps://www.pharmaradar360.com/article/nct07718243-investigating-the-combination-of-bexmarilimab-and-nivolumab-in-solid-f6e5ddf00ca0b40aPharma Surgeen2026-07-21T00:00:00.000ZNCT07718243: Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLChttps://www.pharmaradar360.com/article/nct07717957-comparison-between-mobithron-and-crystalline-glucosamine-sulphate-in-c647043c2d6cf4adPharma Surgeen2026-07-21T00:00:00.000ZNCT07717957: Comparison Between Mobithron® and Crystalline Glucosamine Sulphate in Patients With Knee Osteoarthritishttps://www.pharmaradar360.com/article/nct07717931-vitamin-d-therapy-to-prevent-recurrent-preeclampsia-in-high-risk-pre-99cfab059bd5ac59Pharma Surgeen2026-07-21T00:00:00.000ZNCT07717931: Vitamin D Therapy to Prevent Recurrent Preeclampsia in High-Risk Pregnancieshttps://www.pharmaradar360.com/article/nct07717788-therapeutic-prospects-of-hmg-coa-reductase-inhibitors-atorvastatin-a-68cc04f6cf86b282Pharma Surgeen2026-07-21T00:00:00.000ZNCT07717788: Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patientshttps://www.pharmaradar360.com/article/nct07717710-ivabradine-for-heart-rate-reduction-during-exercise-in-healthy-adult-3c05dde6739b44c2Pharma Surgeen2026-07-21T00:00:00.000ZNCT07717710: Ivabradine for Heart Rate Reduction During Exercise in Healthy Adultshttps://www.pharmaradar360.com/article/nct07717190-long-term-sustainability-of-the-effects-of-dog-assisted-therapy-in-c-97aecf6dbb5dcad3Pharma Surgeen2026-07-21T00:00:00.000ZNCT07717190: Long-term Sustainability of the Effects of Dog-Assisted Therapy in Children and Adolescents With Fetal Alcohol Spectrum Disorder: a 12-month Longitudinal Studyhttps://www.pharmaradar360.com/article/nct07717021-patient-reported-outcome-measures-in-umbilical-hernia-surgery-81decc3affc8eea3Pharma Surgeen2026-07-21T00:00:00.000ZNCT07717021: Patient Reported Outcome Measures in Umbilical Hernia Surgeryhttps://www.pharmaradar360.com/article/nct07716995-association-between-metabolic-associated-fatty-liver-disease-and-obs-f6478878a8ae19e7Pharma Surgeen2026-07-21T00:00:00.000ZNCT07716995: Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apneahttps://www.pharmaradar360.com/article/nct07716865-safety-tolerability-and-efficacy-of-npi-001-in-patients-with-heredit-b8ee893890d19b75Pharma Surgeen2026-07-21T00:00:00.000ZNCT07716865: Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)https://www.pharmaradar360.com/article/nct07716540-analgesic-efficacy-of-ultrasound-guided-deep-iliacus-plane-block-in-0871afe2cab9a11dPharma Surgeen2026-07-21T00:00:00.000ZNCT07716540: Analgesic Efficacy of Ultrasound-Guided Deep Iliacus Plane Block in Patients Undergoing Hip Fracture Surgeryhttps://www.pharmaradar360.com/article/nct07716384-wearable-patch-ultrasound-probe-for-diagnosis-of-liver-stiffness-a2eabc7736c5b56bPharma Surgeen2026-07-21T00:00:00.000ZNCT07716384: Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffnesshttps://www.pharmaradar360.com/article/nct07715903-hepatic-artery-infusion-of-carfilzomib-in-participants-with-liver-me-c34d97c9f5173517Pharma Surgeen2026-07-21T00:00:00.000ZNCT07715903: Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapyhttps://www.pharmaradar360.com/article/nct07714447-efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treat-79bd15e4c8af8821Pharma Surgeen2026-07-21T00:00:00.000ZNCT07714447: Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07713082-therapeutic-exercise-and-education-for-low-back-pain-eb16448c7f7aea34Pharma Surgeen2026-07-21T00:00:00.000ZNCT07713082: Therapeutic Exercise and Education for Low Back Painhttps://www.pharmaradar360.com/article/nct07712237-web-based-advance-care-planning-for-patients-with-advanced-cancer-5d3d19106587b15fPharma Surgeen2026-07-21T00:00:00.000ZNCT07712237: Web-Based Advance Care Planning for Patients With Advanced Cancerhttps://www.pharmaradar360.com/article/nct07690683-patients-with-hepatocellular-carcinoma-hcc-fe4e34449e26a036Pharma Surgeen2026-07-21T00:00:00.000ZNCT07690683: Patients With Hepatocellular Carcinoma (HCC)https://www.pharmaradar360.com/article/nct07683104-natural-history-of-trisomy-8-associated-autoinflammatory-disease-tri-a10b26c09d1352edPharma Surgeen2026-07-21T00:00:00.000ZNCT07683104: Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disordershttps://www.pharmaradar360.com/article/nct07665892-phase-1-study-evaluating-safety-and-pharmacokinetics-of-asy202-in-ad-4ab35ed055d77788Pharma Surgeen2026-07-21T00:00:00.000ZNCT07665892: Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthmahttps://www.pharmaradar360.com/article/nct07664384-general-versus-spinal-anesthesia-in-rirs-3f18fef28f592890Pharma Surgeen2026-07-21T00:00:00.000ZNCT07664384: General Versus Spinal Anesthesia in RIRShttps://www.pharmaradar360.com/article/nct07654426-the-cardioprotect-trial-ea38d9c2bfde6e5aPharma Surgeen2026-07-21T00:00:00.000ZNCT07654426: The CARDIOPROTECT Trialhttps://www.pharmaradar360.com/article/nct07648836-evaluation-of-serum-il-41-level-in-patients-with-ankylosing-spondyli-9d5b982bb197b6c7Pharma Surgeen2026-07-21T00:00:00.000ZNCT07648836: Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritishttps://www.pharmaradar360.com/article/nct07645482-frequency-rhythmic-electrical-modulated-stimulation-effect-in-periph-291a4e1ffe66fbd6Pharma Surgeen2026-07-21T00:00:00.000ZNCT07645482: Frequency Rhythmic Electrical Modulated Stimulation Effect in Peripheral Neuropathy Patients Severity of Cases and Qol.https://www.pharmaradar360.com/article/nct07640802-psychotherapy-for-irritability-in-youth-comparing-active-treatment-t-7d4264b318da1809Pharma Surgeen2026-07-21T00:00:00.000ZNCT07640802: Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapyhttps://www.pharmaradar360.com/article/nct07574541-multitargeted-recombinant-ad5-psa-muc-1-brachyury-based-immunotherap-0f3af0b930fedd23Pharma Surgeen2026-07-21T00:00:00.000ZNCT07574541: Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillancehttps://www.pharmaradar360.com/article/nct07568067-accelerated-temporal-interference-stimulation-on-bilateral-subthalam-3ee1454d80137ccaPharma Surgeen2026-07-21T00:00:00.000ZNCT07568067: Accelerated Temporal Interference Stimulation on Bilateral Subthalamic Nucleus for Parkinson's Disease and Secondary Parkinson's Syndromehttps://www.pharmaradar360.com/article/nct07566481-stress-coping-and-sleep-health-study-bbb76703eb7d29f6Pharma Surgeen2026-07-21T00:00:00.000ZNCT07566481: Stress, Coping, and Sleep Health Studyhttps://www.pharmaradar360.com/article/nct07516548-pharmacokinetic-study-of-long-acting-antiretrovirals-and-contracepti-3425a753dda019acPharma Surgeen2026-07-21T00:00:00.000ZNCT07516548: Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIVhttps://www.pharmaradar360.com/article/nct07506733-effects-of-different-graston-technique-application-speeds-on-trapezi-ec3291d575054a9cPharma Surgeen2026-07-21T00:00:00.000ZNCT07506733: Effects of Different Graston Technique Application Speeds on Trapezius Muscle Stiffness, Pressure Pain Threshold, Pain, and Muscle Oxygenation in Patients With Bruxism